1. Home
  2. HG vs CLDX Comparison

HG vs CLDX Comparison

Compare HG & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Insurance Group Ltd. Class B

HG

Hamilton Insurance Group Ltd. Class B

N/A

Current Price

$38.32

Market Cap

3.8B

Sector

N/A

ML Signal

N/A

Logo Celldex Therapeutics Inc.

CLDX

Celldex Therapeutics Inc.

N/A

Current Price

$27.51

Market Cap

3.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HG
CLDX
Founded
2013
N/A
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.0B
IPO Year
2023
1995

Fundamental Metrics

Financial Performance
Metric
HG
CLDX
Price
$38.32
$27.51
Analyst Decision
Buy
Strong Buy
Analyst Count
7
15
Target Price
$39.86
★ $63.79
AVG Volume (30 Days)
404.0K
★ 723.2K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 5.29%
N/A
EPS Growth
★ 51.23
N/A
EPS
★ 3.54
N/A
Revenue
★ $2,905,524,000.00
$12,743,000.00
Revenue This Year
$0.13
N/A
Revenue Next Year
$2.38
$410.81
P/E Ratio
$10.67
★ N/A
Revenue Growth
24.70
★ 87.78
52 Week Low
$25.53
$22.33
52 Week High
$39.50
$45.14

Technical Indicators

Market Signals
Indicator
HG
CLDX
Relative Strength Index (RSI) 61.13 38.81
Support Level $33.53 $22.46
Resistance Level N/A $31.80
Average True Range (ATR) 0.99 1.52
MACD 0.01 -0.09
Stochastic Oscillator 71.43 15.98

Price Performance

Historical Comparison
HG
CLDX

About HG Hamilton Insurance Group Ltd. Class B

Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.

About CLDX Celldex Therapeutics Inc.

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Share on Social Networks: